Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from IM Cannabis Corp ( (IMCC) ) is now available.
On April 6 and May 7, 2026, IM Cannabis Corp. raised a total of US$550,000 in gross proceeds through two privately placed convertible notes with an institutional lender, each carrying an 8% annual interest rate, rising to 14% on default. The notes are not repayable in cash and will instead be settled in common shares upon conversion, at floating prices tied to recent trading levels but subject to fixed caps and floor prices, with a 4.99% ownership limit to curb concentration.
Alongside the notes, IM Cannabis issued warrants to buy up to 272,861 shares at C$0.47 for the April financing and 1,127,820 shares at C$0.36 for the May financing, both exercisable for five years and subject to a four‑month hold. The company plans to use the net proceeds for general corporate purposes and has committed to reserve sufficient shares and file resale registration statements with the U.S. securities regulator, moves that provide it with near‑term liquidity but introduce potential future equity dilution for existing shareholders.
Spark’s Take on IMCC Stock
According to Spark, TipRanks’ AI Analyst, IMCC is a Neutral.
The score is pressured primarily by weak profitability and a stressed balance sheet (negative equity), which outweigh the 2025 cash-flow improvement. Technically, the stock remains in a strong downtrend below key moving averages, with only oversold signals suggesting a potential (but unconfirmed) stabilization. Valuation is difficult to support due to negative earnings and no dividend information.
To see Spark’s full report on IMCC stock, click here.
More about IM Cannabis Corp
IM Cannabis Corp., listed on Nasdaq as IMCC, is an international medical cannabis company operating primarily in Israel and Germany. Through subsidiaries, it imports and distributes medical cannabis, runs retail pharmacies and online platforms in Israel, and, via Adjupharm GmbH, supplies cannabis to pharmacies serving German medical patients.
The company leverages proprietary patient data and end-to-end control over its supply chain to support product quality and safe delivery, while also evaluating opportunities to expand into additional technology-driven sectors beyond its core medical cannabis operations.
Average Trading Volume: 519,173
Technical Sentiment Signal: Sell
Current Market Cap: $1.6M
Learn more about IMCC stock on TipRanks’ Stock Analysis page.